First published 10/3/2026, 1:25:15 AM · Last updated 10/3/2026, 1:25:15 AM

MA08.05 PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks Plus Lazertinib in First-Line EGFR-Mutated Advanced NSCLC

A journal article published by Elsevier BV on 2025-10-01 describes a study of subcutaneous amivantamab given every four weeks in combination with lazertinib as first-line therapy for EGFR‑mutated advanced non‑small cell lung cancer. The supplied source is the article record only and contains no additional outcome or result details.

Illustrative image: Vero Cell COVID-19 vaccine vial, cotton swab and syringe — Ajay Kumar Chaurasiya/Wikimedia Commons, CC BY-SA 4.0

Categories: public-health, science-and-space

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 4/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 3/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 3/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 5/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article concerns a clinical treatment approach relevant to patients and clinicians treating EGFR‑mutated advanced NSCLC.

Sources

MA08.05 PALOMA-2: Subcutaneous Amivantamab Administered Every 4 Weeks Plus Lazertinib in First-Line EGFR-Mutated Advanced NSCLC

Report an issue